Stay updated with breaking news from Pascal Touchon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
01.02.2024 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and Pierre ... Seite 1
It’s been a rough couple of months for investors in – and employees of – Thousand Oaks-based immunotherapy company Atara Biotherapeutics Inc.
Closing of Transaction with Pierre Fabre Laboratories to Expand Global Tab-cel® Partnership Tab-cel BLA on Track for Submission in Q2 2024 Following Positive New Data from Pivotal ALLELE...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and...
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) have earned an average recommendation of “Hold” from the three analysts that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation. The average 1 year price target among brokers that have updated their coverage on the […]